Sandbox2022
From Proteopedia
| Line 1: | Line 1: | ||
==Your Heading Here (maybe something like 'Structure')== | ==Your Heading Here (maybe something like 'Structure')== | ||
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | ||
| - | This is a default text for your page '''Sandbox2022'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | ||
| - | You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue. | ||
== Function == | == Function == | ||
| Line 8: | Line 6: | ||
== Relevance == | == Relevance == | ||
| - | 사람의 글루타미닐 사이클라아제는 생체 내에서 호모헥사머로 존재한다. QC는 갑상선 종양의 마커로 이용된다. QC는 펩타이드 호르몬의 N-말단 피로글루타밀 그룹과 아밀로이드와 관련된 플라크 형성 펩타이드를 생성한다. 후자는 알츠하이머 병의 원인이 된다. 알츠하이머 환자는 | + | 사람의 글루타미닐 사이클라아제는 생체 내에서 호모헥사머로 존재한다. QC는 갑상선 종양의 마커로 이용된다. QC는 펩타이드 호르몬의 N-말단 피로글루타밀 그룹과 아밀로이드와 관련된 플라크 형성 펩타이드를 생성한다. 후자는 알츠하이머 병의 원인이 된다. 알츠하이머 환자는 QC[2]의 발현이 증가하고, QC억제제는 질병 병리와 증상을 감소시킨다. |
== Structural highlights == | == Structural highlights == | ||
| - | QC의 활성 부위는 Zn+2 이온을 포함한다. | + | QC의 활성 부위는 Zn+2 이온을 포함한다.[3] |
| Line 18: | Line 16: | ||
<references/> | <references/> | ||
| - | + | ↑ Busby WH Jr, Quackenbush GE, Humm J, Youngblood WW, Kizer JS. An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes. J Biol Chem. 1987 Jun 25;262(18):8532-6. PMID:3597387 | |
↑ Valenti MT, Bolognin S, Zanatta C, Donatelli L, Innamorati G, Pampanin M, Zanusso G, Zatta P, Dalle Carbonare L. Increased glutaminyl cyclase expression in peripheral blood of Alzheimer's disease patients. J Alzheimers Dis. 2013;34(1):263-71. doi: 10.3233/JAD-120517. PMID:23207485 doi:http://dx.doi.org/10.3233/JAD-120517 | ↑ Valenti MT, Bolognin S, Zanatta C, Donatelli L, Innamorati G, Pampanin M, Zanusso G, Zatta P, Dalle Carbonare L. Increased glutaminyl cyclase expression in peripheral blood of Alzheimer's disease patients. J Alzheimers Dis. 2013;34(1):263-71. doi: 10.3233/JAD-120517. PMID:23207485 doi:http://dx.doi.org/10.3233/JAD-120517 | ||
↑ Huang KF, Liu YL, Cheng WJ, Ko TP, Wang AH. Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation. Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13117-22. Epub 2005 Aug 31. PMID:16135565 | ↑ Huang KF, Liu YL, Cheng WJ, Ko TP, Wang AH. Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation. Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13117-22. Epub 2005 Aug 31. PMID:16135565 | ||
Revision as of 06:56, 18 July 2018
Your Heading Here (maybe something like 'Structure')
| |||||||||||
References
↑ Busby WH Jr, Quackenbush GE, Humm J, Youngblood WW, Kizer JS. An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes. J Biol Chem. 1987 Jun 25;262(18):8532-6. PMID:3597387 ↑ Valenti MT, Bolognin S, Zanatta C, Donatelli L, Innamorati G, Pampanin M, Zanusso G, Zatta P, Dalle Carbonare L. Increased glutaminyl cyclase expression in peripheral blood of Alzheimer's disease patients. J Alzheimers Dis. 2013;34(1):263-71. doi: 10.3233/JAD-120517. PMID:23207485 doi:http://dx.doi.org/10.3233/JAD-120517 ↑ Huang KF, Liu YL, Cheng WJ, Ko TP, Wang AH. Crystal structures of human glutaminyl cyclase, an enzyme responsible for protein N-terminal pyroglutamate formation. Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13117-22. Epub 2005 Aug 31. PMID:16135565
